Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

被引：0

作者：

Sackstein, Paul E. ^{[1
]}

Chintapally, Nikita ^{[2
]}

Wilgucki, Molly ^{[3
]}

Hartley, Marion L. ^{[1
]}

Alqahtani, Ali ^{[1
]}

Weinberg, Benjamin A. ^{[1
,4
]}

机构：

[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Med Ctr, Washington, DC USA

[2] MedStar Washington Hosp Ctr, Dept Internal Med, Washington, DC USA

[3] Georgetown Univ, Med Ctr, Dept Internal Med, Washington, DC USA

[4] MedStar Georgetown Univ Hosp, 3800 Reservoir Rd NW, Washington, DC 20007 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 11期

关键词：

Acquired resistance; anti-EGFR therapy; epidermal growth factor receptor; metastatic colorectal cancer; GENE COPY NUMBER; COLON-CANCER; MONOCLONAL-ANTIBODIES; ANTITUMOR-ACTIVITY; CETUXIMAB EFFICACY; TARGETING EGFR; KRAS MUTATIONS; ASPIRIN USE; EXPRESSION; INHIBITOR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than 50 years. The epidermal growth factor receptor (EGFR), essential for cell proliferation and survival, has surfaced as a promising therapeutic target for metastatic colorectal cancer and has demonstrated success in various clinical trials. Mono-clonal antibodies such as cetuximab and panitumumab have proven to be effective against EGFR by blocking vital downstream signaling path-ways and inhibiting gene transcription and cell proliferation. Despite this promise, most patients eventually develop resistance to anti-EGFR treatment, thereby limiting its long-term efficacy. Genomic alterations, such as mutations in KRAS, NRAS, and BRAF, often bypass the EGFR receptor, promoting resistance to therapy. Although our understanding of primary resistance to anti-EGFR therapy has improved, acquired resistance remains a significant hurdle. This review explores the potential mechanisms underpinning this acquired resistance and strategies to overcome it.

引用

页码：572 / 583

页数：12

共 111 条

[21] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[22] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[23] Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma [J].

Delord, Jean-Pierre ;

Robert, Caroline ;

Nyakas, Marta ;

McArthur, Grant A. ;

Kudchakar, Ragini ;

Mahipal, Amit ;

Yamada, Yasuhide ;

Sullivan, Ryan ;

Arance, Ana ;

Kefford, Richard F. ;

Carlino, Matteo S. ;

Hidalgo, Manuel ;

Gomez-Roca, Carlos ;

Michel, Daniela ;

Seroutou, Abdelkader ;

Aslanis, Vassilios ;

Caponigro, Giordano ;

Stuart, Darrin D. ;

Moutouh-de Parseval, Laure ;

Demuth, Tim ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2017, 23 (18) :5339-5348

[24] Role of insulin-like growth factor-1R system in colorectal carcinogenesis [J].

Donovan, Erin A. ;

Kummar, Shivaani .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (02) :91-98

[25]

Einstein DJ, 2020, J CLIN ONCOL, V38

[26] Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial [J].

Fakih, Marwan G. ;

Kopetz, Scott ;

Kuboki, Yasutoshi ;

Kim, Tae Won ;

Munster, Pamela N. ;

Krauss, John C. ;

Falchook, Gerald S. ;

Han, Sae-Won ;

Heinemann, Volker ;

Muro, Kei ;

Strickler, John H. ;

Hong, David S. ;

Denlinger, Crystal S. ;

Girotto, Gustavo ;

Lee, Myung-Ah ;

Henary, Haby ;

Tran, Qui ;

Park, Joseph K. ;

Ngarmchamnanrith, Gataree ;

Prenen, Hans ;

Price, Timothy J. .

LANCET ONCOLOGY, 2022, 23 (01) :115-124

[27] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].

Frattini, M. ;

Saletti, P. ;

Romagnani, E. ;

Martin, V. ;

Molinari, F. ;

Ghisletta, M. ;

Camponovo, A. ;

Etienne, L. L. ;

Cavalli, F. ;

Mazzucchelli, L. .

BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145

[28] Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors [J].

Garcia-Foncillas, Jesus ;

Sunakawa, Yu ;

Aderka, Dan ;

Wainberg, Zev ;

Ronga, Philippe ;

Witzler, Pauline ;

Stintzing, Sebastian .

FRONTIERS IN ONCOLOGY, 2019, 9

[29] Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer [J].

Goldberg, Richard M. ;

Montagut, Clara ;

Wainberg, Zev A. ;

Ronga, Philippe ;

Audhuy, Francois ;

Taieb, Julien ;

Stintzing, Sebastian ;

Siena, Salvatore ;

Santini, Daniele .

ESMO OPEN, 2018, 3 (04)

[30] The consensus molecular subtypes of colorectal cancer [J].

Guinney, Justin ;

Dienstmann, Rodrigo ;

Wang, Xin ;

de Reynies, Aurelien ;

Schlicker, Andreas ;

Soneson, Charlotte ;

Marisa, Laetitia ;

Roepman, Paul ;

Nyamundanda, Gift ;

Angelino, Paolo ;

Bot, Brian M. ;

Morris, Jeffrey S. ;

Simon, Iris M. ;

Gerster, Sarah ;

Fessler, Evelyn ;

Melo, Felipe De Sousa E. ;

Missiaglia, Edoardo ;

Ramay, Hena ;

Barras, David ;

Homicsko, Krisztian ;

Maru, Dipen ;

Manyam, Ganiraju C. ;

Broom, Bradley ;

Boige, Valerie ;

Perez-Villamil, Beatriz ;

Laderas, Ted ;

Salazar, Ramon ;

Gray, Joe W. ;

Hanahan, Douglas ;

Tabernero, Josep ;

Bernards, Rene ;

Friend, Stephen H. ;

Laurent-Puig, Pierre ;

Medema, Jan Paul ;

Sadanandam, Anguraj ;

Wessels, Lodewyk ;

Delorenzi, Mauro ;

Kopetz, Scott ;

Vermeulen, Louis ;

Tejpar, Sabine .

NATURE MEDICINE, 2015, 21 (11) :1350-1356

← 1 2 3 4 5 6 7 8 9 10 →